@cbronsonmd's estradiol normal range claims, fact-checked

What did @cbronsonmd actually say?

The core argument here is that standard estradiol reference ranges are built wrong, that estradiol should be interpreted relative to a man's testosterone level rather than as a standalone number. Beyond that, the creator goes further: testosterone "works through estradiol" to deliver its benefits in tissues, and blocking estradiol with an aromatase inhibitor causes harm without a single randomized controlled trial showing benefit. These are not fringe ideas, but they are being stated with more certainty than the evidence fully supports.

The specific warning about keeping estradiol "below 35 or 25" is a direct shot at a common TRT practice of reflexively prescribing anastrozole whenever estradiol creeps up. That critique, at least, has real data behind it.

Does the science back this up?

Partially, yes. The claim that testosterone-to-estradiol ratios matter more than estradiol alone is supported by observational data. The claim that aromatase inhibitor use in eugonadal or TRT men lacks RCT evidence of benefit is accurate. The claim that testosterone "works through" estradiol is a real and published mechanistic theory, not settled consensus.

The most cited evidence comes from Finkelstein et al. (2013, NEJM), which used anastrozole plus testosterone in healthy men and showed that estradiol suppression, not just testosterone, drove changes in fat mass, sexual desire, and bone density. That's a key paper. Antonio et al. (2016, JCEM) added that men on TRT with higher estradiol did not show worse outcomes than those with lower estradiol. Neither paper, however, goes as far as saying testosterone exclusively works "through" estradiol. The biology is more complicated than that framing suggests.

The 600 mg testosterone dose reference appears to be from Bhasin et al. (2001, JCEM), a pharmacological study in healthy young men, not a clinical TRT model. Using it to set expectations for TRT patients is a stretch.

What did they get wrong (or right)?

The creator gets credit for the AI inhibitor critique. The routine prescription of anastrozole to TRT patients based on an absolute estradiol number, rather than symptoms, is not supported by RCT evidence. That is a fair and well-grounded point.

Where things get sloppy is the claim that testosterone works "through estradiol to give you the benefits of testosterone" as a near-universal rule. Testosterone has direct androgenic effects, including via the androgen receptor, that are not mediated by estradiol conversion. Muscle protein synthesis, red blood cell production, and certain cognitive functions have androgen receptor-dependent pathways that do not require aromatization. Finkelstein's own study showed lean mass was primarily androgen-dependent, not estrogen-dependent.

The "not a single RCT" framing is technically defensible but misleading in tone. There are RCTs studying aromatase inhibitors for conditions like male hypogonadism and infertility, and some show clinical utility, though not in the specific context of TRT estradiol management. Saying zero evidence exists overstates the case.

What should you actually know?

If your TRT provider is reflexively prescribing anastrozole every time your estradiol hits 40 pg/mL, that is worth a conversation. The Finkelstein (2013) data genuinely does suggest that estradiol plays a role in libido, fat distribution, and bone health in men, and suppressing it has real costs. But "estradiol does everything" is not the takeaway either.

The ratio argument, that a man with testosterone of 1200 ng/dL will naturally carry more estradiol than one at 400, is physiologically obvious and clinically underappreciated. Most labs still flag estradiol above 42 pg/mL as abnormal without accounting for testosterone level. That is a legitimate systems problem.

What this video should not do is convince anyone to abandon all estradiol management entirely. There are symptomatic men on TRT with elevated estradiol who report gynecomastia, fluid retention, and mood changes that respond to dose reduction or short-term AI use. Those experiences exist even if the RCT literature is thin. Context, symptoms, and shared decision-making matter here, not a blanket rule in either direction.